Erivedge

Vismodegib
Clinical data

Pronunciation	/ˌvɪsmoʊˈdɛɡɪb/ VIS-moh-DEG-ib
Trade names	Erivedge
Synonyms	GDC-0449, RG-3616
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN US FDA: Vismodegib
Pregnancy category	AU: X US: X
Routes of administration	By mouth (capsules)
ATC code	L01XX43 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	31.8%
Protein binding	>99%
Metabolism	<2% metabolised by CYP2C9, CYP3A4, CYP3A5
Biological half-life	4 days (continuous use), 12 days (single dose)
Excretion	Fecal (82%), Urinary (4.4%)
Identifiers
IUPAC name 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
CAS Number	879085-55-9
PubChem CID	24776445
IUPHAR/BPS	6975
DrugBank	DB08828
ChemSpider	23337846
UNII	25X868M3DS
KEGG	D09992
ChEBI	CHEBI:66903^Y
ChEMBL	CHEMBL473417
Chemical and physical data
Formula	C₁₉H₁₄Cl₂N₂O₃S
Molar mass	421.30 g/mol
3D model (JSmol)	Interactive image
SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
InChI InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24) Key:BPQMGSKTAYIVFO-UHFFFAOYSA-N

Vismodegib (trade name Erivedge /ˈɛrɪvɛdʒ/ ERR-i-vej) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011^[update]. The drug was developed by the biotechnology/pharmaceutical company Genentech, which is headquartered at South San Francisco, California, USA.

Vismodegib is indicated for patients with basal cell carcinoma (BCC) which has metastasized to other parts of the body, relapsed after surgery, or cannot be treated with surgery or radiation.

...
Wikipedia